Peptide basics

BPC-157: 31,331 readers a month, 2 registered trials

This page compares readership figures with registry entries. It makes no claim that BPC-157 is effective, ineffective, safe, unsafe, or appropriate for anyone, and it contains no dose, route, or schedule information.

The two numbers

The English Wikipedia article on BPC-157 averaged 31,331 views a month across the complete months between February and June 2026, with a peak month of 35,706. The figure comes from the Wikimedia pageviews API, which measures encyclopedia readership rather than search volume or purchasing.⁶

Over the same period, ClinicalTrials.gov held 2 records naming BPC-157 as an intervention. Not two hundred, not twenty. Two. It is the widest gap between attention and registered evidence among the 68 compounds this site tracks, and it is wide by a large margin.¹²

What is actually in those two records

NCT02637284

Registered in December 2015 by PharmaCotherapia d.o.o., with a stated start of October 2015. It is a phase 1 safety and pharmacokinetics trial with a planned enrolment of 42. The intervention is registered under the name Bepecin, with BPC-157 and the sponsor code PCO-02 recorded in the other-names field — which is why a search on the compound name alone can miss it. Its registry status is unknown, the state ClinicalTrials.gov assigns when a record has passed its expected completion date without a sponsor update.¹

NCT07437547

Registered by Hudson Biotech, with a start date of 2 February 2026 and a status of recruiting. It is a phase 2, placebo-controlled trial in acute hamstring muscle strain with a planned enrolment of 120. It is the first phase 2 registration naming this compound, and at the time of writing it had been open for under six months.²

What exists instead

The gap is not empty. It is filled with preclinical work, and a 2025 systematic review in HSS Journal counted it: searching PubMed, Cochrane and Embase from database inception to June 2024, the authors screened 544 articles and included 36 studies — 35 preclinical and one clinical. The single clinical study was a retrospective report of 12 patients treated for chronic knee pain. The review states that no clinical safety data were found.³

Thirty-five to one is the ratio worth carrying away. It is not a criticism of the preclinical work, which is a legitimate stage of drug development and often good science. It is a description of where this compound sits in that development pipeline: at the beginning of it, with one phase 1 record of uncertain fate and one phase 2 record five months old.²³

There is also an earlier chapter that a registry search will not surface. A 2006 paper describes BPC-157 under the sponsor codes PL-10, PLD-116 and PL 14736 in the context of inflammatory bowel disease work at Pliva in Croatia — development activity that predates the 2017 effective date of the US registration rule and that a search on the modern name does not retrieve. A 2026 review of the compound's formulation and translational challenges places it, in its own title, as an investigational peptide therapeutic.⁴⁷⁸

The regulatory line, stated exactly

BPC-157 appears on the FDA's published list of bulk drug substances assessed for compounding, in the section for substances whose nominations were withdrawn after having been placed in the significant-safety-risk category. The agency's stated reason is worth reading literally: compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities regarding peptide-related impurities and characterisation, and the agency has identified no, or only limited, safety-related information for the proposed routes of administration — therefore it lacks sufficient information to know whether the drug would cause harm.⁵

That is a statement about missing information, not a finding of harm, and it is also not a clearance. It is the regulator describing the same hole this page describes, from its own review, in its own words.⁵

Why the gap persists

Registered trials are expensive and are usually run by someone who expects to own an approved product at the end. A compound already widely available outside a regulated supply chain offers a weak commercial case for that spend, which is one ordinary explanation for a thin registry record that has nothing to do with whether the molecule is interesting.

That explanation cuts against a comforting reading in both directions. It means the empty record is not proof that the compound failed. It also means the reader should not expect the record to fill in on its own: absent a sponsor with a licence to win, the studies that would answer the question do not get funded, and the attention keeps arriving anyway.²³